ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "axial spondyloarthritis"

  • Abstract Number: 2777 • 2019 ACR/ARP Annual Meeting

    What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts

    Alexandre Sepriano1, Sofia Ramiro 2, Désirée van der Heijde 1, Pierre Hoonhout 3, Anna Moltó 4, Alain Saraux 5, Maxime Dougados 6 and Robert B.M. Landewé 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3ISEG - Lisbon School of Economics and Management, Lisbon, Portugal, 4Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 5CHU de la Cavale-Blanche Brest, Brest, France, 6Cochin Hospital, Paris, France, 7Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria,…
  • Abstract Number: 568 • 2019 ACR/ARP Annual Meeting

    Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility

    Farhan Syed1, Kassel Fotinos-Hoyer 2, Michael O'Connor 3, Maureen Li 3, Bryan Hermannsson 2, Nicholas Enus 3, Sayali Karve 3, Manish Sharma 4, Gabriele Pradella 3, Robert B.M. Landewé 5, Xenofon Baraliakos 6 and Sarah Warner 3, 1Parexel, Billerica, MA, 2Parexel, Berlin, Germany, 3Parexel, Billerica, 4Parexel, Hyderabad, India, 5Amsterdam University Medical Center, Amsterdam, Netherlands, 6Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…
  • Abstract Number: 606 • 2019 ACR/ARP Annual Meeting

    Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort

    Marion Pons 1, Sylvie Chevret 2, Karine Briot 3, Maria-Antonietta D’Agostino 4, Christian Roux 5, Maxime Dougados 6 and Anna Moltó5, 1Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, 2INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, 3Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, 4Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, 5Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, 6Cochin Hospital, Paris, France

    Background/Purpose: Contradictory data has been reported on the effectiveness of a second and third line of TNFi in early axial spondyloarthritis (axSpA). The objective of…
  • Abstract Number: 851 • 2019 ACR/ARP Annual Meeting

    Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort

    Santiago Rodrigues-Manica1, Alexandre Sepriano 2, Sofia Ramiro 3, Robert B.M. Landewé 4, Pascal Claudepierre 5, Anna Molto 6, Maxime Dougados 7, Miranda van Lunteren 2 and Désirée van der Heijde 2, 1CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, 2Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 4Amsterdam University Medical Center, Amsterdam, Netherlands, 5Rheumatology, CHU Henri Mondor Créteil, Paris, France, 6Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, 7Cochin Hospital, Paris, France

    Background/Purpose: The overall presence of inflammation in the MRI-SIJ is associated with overall 5-year radiographic damage in patients with axSpA. But we do not know…
  • Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting

    Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial

    Fabian Proft1, Murat Torgutalp 2, Anja Weiß 3, Mikhail Protopopov 4, Valeria Rios Rodriguez 5, Hildrun Haibel 1, Olaf Behmer 6, Joachim Sieper 1 and Denis Poddubnyy 7, 1Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, 3German Rheumatism Research Center (DRFZ), Berlin, Germany, 4Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, 5Charité Universitätsmedizin, Berlin, Germany, 6Pfizer Inc., Berlin, Germany, 7Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany

    Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…
  • Abstract Number: 1549 • 2019 ACR/ARP Annual Meeting

    Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab

    Cheng-Chung Wei1, Lianne Gensler 2, Jessica Walsh 3, Robert B.M. Landewé 4, Tetsuya Tomita 5, Fangyi Zhao 6, Gaia Gallo 6, Hilde Carlier 7 and Maxime Dougados 8, 1Chung Shan Medical University, Taichung City, Taiwan (Republic of China), 2University San Francisco California, San Francisco, CA, 3Division of Rheumatology, University of Utah, Salt Lake City, UT, 4Amsterdam University Medical Center, Amsterdam, Netherlands, 5Osaka University Graduate School of Medicine, Osaka, Japan, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly and Company, Indianapolis, 8Hôpital Cochin, Paris, France

    Background/Purpose: During 16 weeks of blinded treatment, ixekizumab (IXE) and an adalimumab (ADA) active reference arm were found superior to placebo (PBO) in improving signs…
  • Abstract Number: 2778 • 2019 ACR/ARP Annual Meeting

    Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)

    Hong Ki Min1, Seung-Ki Kwok 2 and Sang-Heon Lee 1, 1Konkuk university medical center, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort…
  • Abstract Number: 573 • 2019 ACR/ARP Annual Meeting

    Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study

    Xenofon Baraliakos1, Adrian Richter 2, Daniel Feldmann 3, Anne Ott 3, Robin Buelow 4, Carsten Oliver Schmidt 5 and Jürgen Braun 6, 1Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 2Institute for Community Medicine, University Greifswald, and German Rheumatism Research Center, Berlin, Berlin, Germany, 3Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 4Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany, 5Institute for Community Medicine, University Greifswald, Greifswald, Germany, 6Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Active (bone marrow edema, BME) and structural (fatty lesions, FL) lesions in the spinal and the sacroiliac joints (SIJ), as assessed by magnetic resonance…
  • Abstract Number: 607 • 2019 ACR/ARP Annual Meeting

    Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis

    Adam Lefferts1, Emilie Regner 2, Andrew Stahly 3, Rebecca O'Rourke 1, Kenneth Jones 2 and Kristine Kuhn 1, 1University of Colorado, Anschutz Medical Campus, Aurora, CO, 2University of Colorado, Anschutz Medical Campus, Denver, CO, 3University of Colorado, Aurora, CO

    Background/Purpose: Background: The clinical overlap of axial spondyloarthritis (axSpA) and Crohn’s disease (CD) has given rise to the hypothesis that these conditions may share pathophysiologic…
  • Abstract Number: 854 • 2019 ACR/ARP Annual Meeting

    Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort

    Elena Nikiphorou1, Sofia Ramiro 2, Alexandre Sepriano 3, Adeline Ruyssen Witrand 4, Robert B.M. Landewé 5 and Désirée van der Heijde 3, 1King's College London, London, United Kingdom, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology center, Pierre Paul Riquet Hospital, CHU of Toulouse, Paul Sabatier University, UMR 1027, Inserm, France, Toulouse, France, 5Amsterdam University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Smoking and systemic inflammation have been shown to independently associate with radiographic spinal progression in patients with axSpA. Evidence suggests that certain socioeconomic (SE)…
  • Abstract Number: 1492 • 2019 ACR/ARP Annual Meeting

    Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study

    Mohamed Ismail1, Ahmed Nader 1, Insa Winzenborg 2, In-Ho Song 3 and Ahmed Othman 1, 1AbbVie Inc., North Chicago, IL, 2AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany, 3AbbVie Inc., North Chicago, IL, USA, North Chicago, IL

    Background/Purpose: Upadacitinib, a selective inhibitor of Janus kinase 1 (JAK1), is currently being evaluated for the treatment of several autoimmune disorders, including axial spondyloarthritis (axial…
  • Abstract Number: 1551 • 2019 ACR/ARP Annual Meeting

    Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration

    Lykke Midtbøll Ørnbjerg 1, Cecilie Heegaard Brahe1, Anne Gitte Loft 2, Johan Askling 3, Adrian Ciurea 4, Herman Mann 5, Servet Akar 6, Eirik Kristianslund 7, Dan Nordström 8, Maria José Santos 9, Catalin Codreanu 10, Manuel Pombo-Suarez 11, Ziga Rotar 12, Bjorn Gudbjornsson 13, Daniela DiGuiseppe 14, Michael J. Nissen 15, Karel Pavelka 5, Soner Senel 16, Joe Sexton 17, Kari K. Eklund 18, Anabela Barcelos 19, Ruxandra IONESCU 20, Carlos Sánchez-Piedra 21, Matija Tomsic 22, Arni Jon Geirsson 23, Irene van der Horst-Bruinsma 24, Gary Macfarlane 25, Florenzo Iannone 26, Brigitte Michelsen 1, Lise Hyldstrup 27, Niels Steen Krogh 28, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, 2Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 3Karolinska Institutet, Stockholm, Sweden, 4University Hospital Zürich, Zürich, Switzerland, 5Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 6Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 7Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 8Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 11Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, 12UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 13Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 14Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 15University Hospital Geneva, Geneva, Switzerland, 16Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, 17Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 18ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 19Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, 20SPITALUL CLINIC SFANTA MARIA, Bucharest, 21Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 22Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 24Amsterdam University Medical Center, Amsterdam, Netherlands, 25University of Aberdeen, Aberdeen, United Kingdom, 26Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28Zitelab / DANBIO, Copenhagen, Denmark, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with axial spondyloarthritis (axSpA), but still some patients switch to a different TNFi because of…
  • Abstract Number: 2779 • 2019 ACR/ARP Annual Meeting

    Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors

    Alexandre Sepriano1, Sofia Ramiro 2, Stephanie Wichuk 3, Praveena Chiowchanwisawakit 4, Terrie MacCosham 3, Joel Paschke 5, Désirée van der Heijde 1, Robert B.M. Landewé 6 and Walter Maksymowych 7, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, 3University of Alberta, Edmonton, Canada, 4Mahidol University, Bangkok, Thailand, 5CARE Arthritis, Edmonton, Canada, 6Amsterdam University Medical Center, Amsterdam, Netherlands, 7University of Alberta and CARE Arthritis, Edmonton, Canada

    Background/Purpose: The association between disease activity and spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) has been previously shown in a cohort of patients (pts)…
  • Abstract Number: 577 • 2019 ACR/ARP Annual Meeting

    Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients

    Ann-Sophie De Craemer1, Thomas Renson 1, Liselotte Deroo 1, Manouk de Hooge 1, Philippe Carron 1, Filip Van den Bosch 1 and Dirk Elewaut 1, 1Ghent University Hospital, Ghent, Belgium

    Background/Purpose: Disease activity in axial spondyloarthritis (axSpA) is often quantified by the Ankylosing Spondylitis Disease Activity Score (ASDAS), a composite index which combines 4 patient…
  • Abstract Number: 608 • 2019 ACR/ARP Annual Meeting

    Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls

    Freke Wink1, Thomas Diemel 2, Suzanne Arends 2 and Anneke Spoorenberg 2, 1Medical Center Leeuwarden, Leeuwarden, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Enthesitis is one of the features of ankylosing spondylitis (AS). High prevalence of structural and inflammatory ultrasound lesions of peripheral entheses are found in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology